Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of intravitreal DE-109 (sirolimus) for non-infectious posterior uveitis
2011-001595-19Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirolimus in non-infectious posterior uveitis (NIPU) and posterior uveitis (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Proportion of subjects with improvement in vitreous haze score. Started Jun 2011; status: completed.
02
Drugs
sirolimus
03
Conditions
non-infectious posterior uveitis (NIPU)posterior uveitis
Beyond the preview
Go deeper on 2011-001595-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001595-19.